Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:HURA NASDAQ:SCYX NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.79-2.1%$0.85$0.55▼$1.66$103.98M0.921.38 million shs898,409 shsHURATuHURA Biosciences$2.62-1.5%$2.60$1.80▼$8.63$116.19M0.04215,695 shs69,339 shsSCYXSCYNEXIS$0.73+3.2%$0.76$0.66▼$1.94$27.67M1.64200,066 shs354,921 shsSKYESkye Bioscience$3.89+2.6%$3.37$1.14▼$7.47$117.39M2.21402,714 shs437,126 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-2.14%-9.66%-6.86%-2.72%-34.89%HURATuHURA Biosciences-1.50%+1.55%+9.17%-33.72%+261,999,900.00%SCYXSCYNEXIS+3.24%+4.59%+3.42%-23.53%-62.27%SKYESkye Bioscience+2.64%+7.76%-11.39%+117.32%-30.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Genetics2.5948 of 5 stars3.74.00.00.01.81.70.0HURATuHURA Biosciences1.2803 of 5 stars3.70.00.00.01.10.00.0SCYXSCYNEXIS0.4243 of 5 stars0.04.00.00.00.00.80.6SKYESkye Bioscience1.4722 of 5 stars3.52.00.00.01.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17682.77% UpsideHURATuHURA Biosciences 3.40Buy$12.67383.46% UpsideSCYXSCYNEXIS 0.00N/AN/AN/ASKYESkye Bioscience 3.00Buy$16.60326.74% UpsideCurrent Analyst Ratings BreakdownLatest SCYX, ATOS, SKYE, and HURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.006/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/6/2025ATOSAtossa GeneticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.25 ➝ $7.506/5/2025ATOSAtossa GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$4.005/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/AHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/ASCYXSCYNEXIS$3.75M7.62N/AN/A$1.45 per share0.50SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.21N/AN/AN/AN/A-33.90%-31.53%8/11/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A291.69%122.09%10/6/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.56N/A14.64N/A-1,030.04%-53.47%-32.86%8/14/2025 (Estimated)SKYESkye Bioscience-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/ALatest SCYX, ATOS, SKYE, and HURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SCYXSCYNEXIS-$0.23N/AN/AN/AN/AN/A8/11/2025Q2 2025ATOSAtossa Genetics-$0.06N/AN/AN/AN/AN/A5/15/2025Q1 2025HURATuHURA Biosciences-$0.13-$0.15-$0.02-$0.15N/AN/A5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million5/13/2025Q1 2025ATOSAtossa Genetics-$0.06-$0.05+$0.01-$0.05N/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A12.6712.67HURATuHURA BiosciencesN/A3.003.00SCYXSCYNEXISN/A5.835.83SKYESkye BioscienceN/A11.8511.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%HURATuHURA Biosciences0.62%SCYXSCYNEXIS54.37%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics7.60%HURATuHURA Biosciences0.20%SCYXSCYNEXIS4.86%SKYESkye Bioscience4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million119.35 millionOptionableHURATuHURA BiosciencesN/A43.68 million43.59 millionN/ASCYXSCYNEXIS6039.02 million37.12 millionOptionableSKYESkye Bioscience1130.98 million29.58 millionOptionableSCYX, ATOS, SKYE, and HURA HeadlinesRecent News About These CompaniesWe Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth CarefullyAugust 6 at 2:16 AM | finance.yahoo.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Average PT from AnalystsJuly 31, 2025 | americanbankingnews.comSkye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025July 30, 2025 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by AnalystsJuly 28, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Shares Down 8% - What's Next?July 25, 2025 | marketbeat.comSKYE Stock Price Quote | MorningstarJuly 11, 2025 | morningstar.comMSkye Bioscience, Inc. (SKYE) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSkye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a DataJuly 6, 2025 | msn.comPositive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past yearJune 25, 2025 | finance.yahoo.comSkye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...June 24, 2025 | manilatimes.netMSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - MorningstarJune 24, 2025 | morningstar.comMSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - NasdaqJune 24, 2025 | nasdaq.comSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity TreatmentJune 23, 2025 | quiverquant.comQSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific SessionsJune 23, 2025 | globenewswire.comSkye confirms phase 2 data on nimacimab for obesity expected later this yearJune 19, 2025 | msn.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific SessionsJune 17, 2025 | finance.yahoo.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific SessionsJune 17, 2025 | globenewswire.com3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesMay 23, 2025 | zacks.comSkye Bioscience to Participate in Upcoming Investment ConferencesMay 22, 2025 | globenewswire.comSkye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity TreatmentMay 21, 2025 | nasdaq.comQ&A: Next wave of obesity drugs may ‘afford a lot of advantages’May 20, 2025 | healio.comHNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and WhyBy Leo Miller | July 16, 2025View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and WhyKratos Defense Is Changing Warfare—Here’s What’s Driving ItBy Jeffrey Neal Johnson | July 24, 2025View Kratos Defense Is Changing Warfare—Here’s What’s Driving ItSCYX, ATOS, SKYE, and HURA Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.79 -0.02 (-2.14%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$0.82 +0.03 (+4.09%) As of 05:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.TuHURA Biosciences NASDAQ:HURA$2.62 -0.04 (-1.50%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$2.80 +0.18 (+6.87%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.SCYNEXIS NASDAQ:SCYX$0.73 +0.02 (+3.24%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$0.63 -0.10 (-13.93%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Skye Bioscience NASDAQ:SKYE$3.89 +0.10 (+2.64%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$3.97 +0.08 (+2.08%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
